Li et al. reported that NT5DC3 can be used as a biomarker to discriminate patients with type 2 diabetes (T2D) and T2D-induced colon cancer from healthy volunteers by detecting the expression level of NT5DC3 in the blood 13. The gene discussed is NT5DC3; the disease is malignant colon neoplasm.